CSL is confident it can make an updated version of AstraZeneca’s COVID-19 vaccine to cover any virus variants that might arise – putting the ball in the medical regulator’s court for a quick approval.
It comes as the Australian pharma giant prepares to begin the process of bottling the first doses of the life-saving vaccine in the coming days.
CSL’s Chief Scientific Officer, Dr Andrew Nash, with a replica of the vial of the cells that will enter a bioreactor to replicate and make 30 million doses of the University of Oxford/AstraZeneca vaccine.Credit:Chris Hopkins
A small South African study sent shockwaves around the world this week after it found AstraZeneca’s vaccine was only about 10 per cent efficacious against the South African variant; that nation’s government soon paused the roll-out of the vaccine. AstraZeneca has said it is working on a booster jab, which will be released within the year.
Scientists remain hopeful the original vaccine will still provide protection against serious illness and death.
Dr Andrew Nash, CSL’s chief scientific officer, told The Age and The Sydney Morning Herald that editing the vaccine to cover variants would be quick and easy. Once AstraZeneca supplied the updated materials, CSL could immediately begin production.
The bigger question, Dr Nash said, would be whether the Therapeutic Goods Administration would approve an edited vaccine immediately or require it to go through an additional round of clinical trials.
Scientists working in CSL’s production facility for the AstraZeneca vaccine on Thursday.Credit:Jason South
A vaccination campaign is expected to begin in March, the federal government has said. CSL hopes to make more than one million doses a week when at full production.
AstraZeneca’s viral-vector technology inserts the genetic code for SARS-CoV-2’s spike protein inside a virus common to chimpanzees, which then infects human cells after vaccination. The cells read the code and produce the spike protein, prompting the human immune system to generate antibodies that can neutralise it.
However, the immune system also naturally raises antibodies to the chimpanzee virus – leading some scientists to raise concerns it may not be possible to boost the AstraZeneca vaccine, if a booster is needed to cover emerging variants.
“Eventually, those antibodies may block the [chimpanzee virus] vector from getting inside the cell to make the spike protein,” Associate Professor Corey Smith, head of translational and human immunology at the QIMR Berghofer Medical Research Institute in Brisbane, said earlier this week.
“Are they going to be able to make new vaccines every year? You probably make antibodies to the vector. It may still be OK, but that’s also an unknown.”
Dr Nash dismissed those concerns. If a booster was required, AstraZeneca could select an alternative virus for use in the vaccine, he said.
“The format might have to be changed, but we will work that out.”
Science and health explained and analysed with a rigorous focus on the evidence. Examine is a weekly newsletter by science reporter Liam Mannix. Sign up to receive it every Tuesday.
Most Viewed in National
Source: Read Full Article